Clinical trial Recruiting at 13 sites Phase 4 Interventional Ages 4 to 17

Comparing medications for ADHD in children with autism

Official title: Comparative Effectiveness of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder

Run by Nationwide Children's Hospital · NCT05916339 · Data updated 2026-11-12

This study is testing two ADHD medications to see which works better for children with autism and how parents can help track their effectiveness.

Quick facts

PhasePhase 4
Study typeInterventional
Ages4 Years to 17 Years
SexAll
Enrollment500 (estimated)
SponsorNationwide Children's Hospital
Academic / other
Locations13 sites (Irvine, California and 12 other locations)
StatusRecruiting
StartedOctober 1, 2023
Main results expectedJanuary 1, 2027
Study endsDecember 30, 2027
Registry record updatedOctober 22, 2026
Trial IDNCT05916339 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are children and adolescents aged 4 to 17 with confirmed diagnoses of both autism spectrum disorder and ADHD.

Probably not a fit

Patients who do not have a diagnosis of ADHD or autism spectrum disorder may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial examines the effectiveness of two stimulant medications, methylphenidate and amphetamine, in treating ADHD in children and adolescents diagnosed with autism spectrum disorder (ASD). Utilizing a sequential, multiple assignment randomization trial (SMART) design, the study also explores the role of alpha-2 agonists in medication management. The goal is to enhance clinicians' understanding of medication options and improve treatment outcomes for patients with co-occurring ADHD and ASD. Parents will play an active role in assessing medication effectiveness and guiding adjustments based on their observations and discussions with healthcare providers.

Why it matters

Potential benefit: If successful, this study could lead to more effective medication management for children with ADHD and autism, improving their overall quality of life.

How similar studies have gone: Other studies have shown varying success with similar approaches, but this specific combination of ADHD medications in ASD patients is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Participant and/or legal caregiver must be willing and able to give informed consent/assent for participation in this study.
2. Participant and/or legal caregiver must be willing and able (in the Investigator's opinion) to comply with all study requirements.
3. Participant must be between 4 and 17 years of age (inclusive) at time of enrollment.
4. Participant must have a confirmed diagnosis of ASD based on supportive evidence (e.g. referring physician's report, medical records, such as ADOS or CARS, etc.).
5. Participant must have the ability to consistently take medication (via pill, liquid or mixed with food/liquid).
6. Participant must have a confirmed diagnosis of ADHD (based upon DSM-5 criteria and supportive evidence).
7. Participant must have a consistent reporter (e.g., parent) who spends regular time with the child.
8. Participant can be on other psychotropic medications (selective serotonin reuptake inhibitor (SSRI), atypical antipsychotic, anticonvulsant) if dose has been stable for \> 4 weeks prior to consent with no plans for a dose change during the study.
9. It has been at least 7 days since the participant last took an ADHD medication and the presiding clinician believes this to be a sufficient amount of time.
10. Caregiver must be sufficiently fluent in English or Spanish to be able to complete questionnaires relevant to this study.

Exclusion Criteria:

1. Participant has taken ADHD medication within the past 7 days.
2. Participant is not stable on other medications (\< 4 weeks).
3. Any other risk factor that might prevent patient from safely taking the study medications.

   * There are no inclusion/exclusion criteria based upon participant IQ. We will include individuals across the entire range of cognition, just as practitioners are asked to treat ADHD in children with ASD across the entire IQ range.

Where it's running

  • University of California, Irvine
    Irvine, California, United States
    Recruiting
  • Children's Hospital Los Angeles
    Los Angeles, California, United States
    Recruiting
  • Maine Medical Center
    Portland, Maine, United States
    Recruiting
  • Massachusetts General Hospital Lurie Center for Autism
    Boston, Massachusetts, United States
    Recruiting
  • University of Rochester
    Rochester, New York, United States
    Recruiting
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio, United States
    Recruiting
Show 7 more locations
  • Nationwide Children's Hospital
    Columbus, Ohio, United States
    Recruiting
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania, United States
    Recruiting
  • University of Pittsburgh
    Pittsburgh, Pennsylvania, United States
    Recruiting
  • Prisma Health Upstate
    Greenville, South Carolina, United States
    Recruiting
  • University of Virginia
    Charlottesville, Virginia, United States
    Recruiting
  • University of Alberta, Glenrose Rehabilitation Hospital
    Edmonton, Canada
    Recruiting
  • Holland Bloorview Kids Rehabilitation Hospital
    Toronto, Canada
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.